Acute Gout Flare (Inpatient)

https://is1-ssl.mzstatic.com/image/thumb/Podcasts122/v4/0a/32/9f/0a329f7c-9862-b698-cf69-49fc69e39d4a/mza_713703518444843042.jpg/600x600bb.jpg

The Point of Care Podcast

RMO Medical Education

35 episodes

6 days ago

The Point of Care Podcast provides high-yield medical information to help clinicians effectively and efficiently manage patients with common medical complaints. The show is based on the templates featured on pointofcaremedicine.com, which aim to standardize common patient encounters and promote evidence-based practices.

Medicine

Health & Fitness

RSS

All content for The Point of Care Podcast is the property of RMO Medical Education and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/35719149/35719149-1670966442943-b4ee30865f255.jpg

Acute Gout Flare (Inpatient)

The Point of Care Podcast

16 minutes 5 seconds

2 years ago

Acute Gout Flare (Inpatient)

Visit pointofcaremedicine.com to see the templates, pearls, literature, and other resources discussed in this episode.

Our mission is to create accessible and easy-to-use digital resources that help healthcare professionals tackle common clinical presentations at the point of care, without getting bogged down by unnecessary details or trivia.

Time Stamps:

00:00:08 - Background and Definitions

00:01:39 - Pathophysiology

00:03:22 - Admission Checklist

00:04:25 - HPI Intake

00:05:51 - Physical Exam

00:06:06 - Differential Diagnosis

00:06:38 - Plan - Workup and Treatment

00:08:54 - If You Remember Nothing Else

00:10:14 - Pearls - Etiology

00:11:00 - Pearls - Presentation and Diagnosis

00:13:07 - Pearls - Treatment

00:15:20 - Literature and Trials

00:15:56 - Wrap Up

Show Notes:

Gout Review (NEJM, 2022)STOP Gout Trial (NEJM, 2022) - allopurinol non-inferior to febuxostat for preventing flares and for reaching target urate concentrations at 48 weeks CARES Trial (NEJM, 2018) suggested an increased risk of mortality in febuxostat from cardiac events, but a follow-up FAST Trial (Lancet, 2020) showed no difference compared to allopurinol - FDA still has a black box warning Calcium Pyrophosphate Deposition Disease (CPPD) Review (NEJM, 2016)